$1.002 Billion

Mirati Therapeutics

Follow-on Offering

Bookrunner, October 2020

Mirati Therapeutics, Inc. is a clinical-stage oncology company developing product candidates to address the genetic and immunological promoters of cancer. The Company’s KRAS inhibitor programs are focused on developing novel inhibitors of KRAS mutations and include one clinical program and a preclinical program. In immune-oncology, the Company is advancing its kinase inhibitor clinical program where its product candidate has the potential to improve the immune environment of tumor cells and enhance and expand the efficacy of existing cancer immunotherapy medicines when given in combination. The Company also has additional preclinical programs which include product candidates specifically designed to address mutations and tumors where few treatment options exist. The Company’s clinical programs consist of two product candidates: MRTX849 (adagrasib is the provisionally filed name for MRTX849), a KRAS G12C inhibitor, and sitravatinib, a multi-kinase inhibitor. The Company’s preclinical pipeline includes MRTX1133, a KRAS G12D inhibitor, and other discovery stage programs.